Evidence map›Paper›PMID 26871468›Full record

ArticleOncotarget2016

Mutant p53 protects ETS2 from non-canonical COP1/DET1 dependent degradation.

Zunamys I Carrero, Madhusudhan Kollareddy, Krishna M Chauhan, Gopalakrishnan Ramakrishnan, Luis A Martinez

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Zunamys I CarreroDepartment of Biochemistry, The University of Mississippi Medical Center, Jackson, MS 39216, USA.
Madhusudhan KollareddyDepartment of Biochemistry, The University of Mississippi Medical Center, Jackson, MS 39216, USA.
Krishna M ChauhanDepartment of Biochemistry, The University of Mississippi Medical Center, Jackson, MS 39216, USA.
Gopalakrishnan RamakrishnanDepartment of Biochemistry, The University of Mississippi Medical Center, Jackson, MS 39216, USA.
Luis A MartinezDepartment of Pathology and Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA.
University of Mississippi · USUniversity of Mississippi Medical Center · USStony Brook University · US

Funding

Transcriptional Regulations of Oncongenic Properties of Mutant P53R01CA166974 · NCI · UNIVERSITY OF MISSISSIPPI MED CTR · PI Luis Alfonso Martinez · 2013 to 2026
$3.3M
NCI NIH HHS R01 CA166974
6 · The paper itself

Abstract

Mutations in the tumor suppressor gene TP53 contribute to the development of approximately half of all human cancers. One mechanism by which mutant p53 (mtp53) acts is through interaction with other transcription factors, which can either enhance or repress the transcription of their target genes. Mtp53 preferentially interacts with the erythroblastosis virus E26 oncogene homologue 2 (ETS2), an ETS transcription factor, and increases its protein stability. To study the mechanism underlying ETS2 degradation, we knocked down ubiquitin ligases known to interact with ETS2. We observed that knockdown of the constitutive photomorphogenesis protein 1 (COP1) and its binding partner De-etiolated 1 (DET1) significantly increased ETS2 stability, and conversely, their ectopic expression led to increased ETS2 ubiquitination and degradation. Surprisingly, we observed that DET1 binds to ETS2 independently of COP1, and we demonstrated that mutation of multiple sites required for ETS2 degradation abrogated the interaction between DET1 and ETS2. Furthermore, we demonstrate that mtp53 prevents the COP1/DET1 complex from ubiquitinating ETS2 and thereby marking it for destruction. Mechanistically, we show that mtp53 destabilizes DET1 and also disrupts the DET1/ETS2 complex thereby preventing ETS2 degradation. Our study reveals a hitherto unknown function in which DET1 mediates the interaction with the substrates of its cognate ubiquitin ligase complex and provides an explanation for the ability of mtp53 to protect ETS2.

Indexed as

MutationA549 CellsCarrier ProteinsGene Knockdown TechniquesGenes, p53HumansProto-Oncogene Protein c-ets-2TransfectionTumor Suppressor Protein p53Ubiquitin-Protein LigasesCarrier ProteinsCOP1 protein, humanDET1 protein, humanETS2 protein, humanProto-Oncogene Protein c-ets-2TP53 protein, humanTumor Suppressor Protein p53Ubiquitin-Protein Ligasesconstitutive photomorphogenesis protein 1 (COP1)de-etiolated 1 (DET1)erythroblastosis virusE26 oncogene homologue 2 (ETS2)mutant p53protein stability

Identifiers

PMID26871468
PMCPMC4914304
OpenAlexW2300600392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.